Free shipping on all orders over $ 500

Ralimetinib dimesylate

Cat. No. M2318

All AbMole products are for research use only, cannot be used for human consumption.

Ralimetinib dimesylate Structure
Synonym:

LY2228820 dimesylate; LY2228820 2MsOH

Size Price Availability Quantity
1mg USD 35  USD35 In stock
1mg USD 35  USD35 In stock
2mg USD 55  USD55 In stock
5mg USD 85  USD85 In stock
10mg USD 140  USD140 In stock
50mg USD 310  USD310 In stock
100mg USD 480  USD480 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Ralimetinib dimesylate (LY2228820 dimesylate) is a novel and potent p38MAPK inhibitor. In vitro kinase enzyme activity showed that the IC50 for p38αMAPK and p38βMAPK of LY2228820 were 7 nM and 3 nM, respectively. Phosphorylation of MAPKAPK2 and/or HSP27, down stream targets of p38MAPK, was significantly inhibited by LY in both MM cell lines and LT-BMSCs.

Customer Product Validations & Biological Datas
Source Oncotarget (2016). Figure 3. LY2228820
Method colony assays
Cell Lines MDA-MB-231 cells
Concentrations 10 μM
Incubation Time 72 h
Results The triple combination significantly retarded shortterm proliferation of MDA-MB-231 cells compared to vehicle and single drug controls (p<0.001), as well as the two-agent combinations
Chemical Information
Molecular Weight 612.74
Formula C24H29FN6.2CH4O3S
CAS Number 862507-23-1
Solubility (25°C) DMSO 30 mg/mL
Water 33 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Ann-Kathrin Reuschl, et al. Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant

[2] J Biau, et al. Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma

[3] Jian Wang, et al. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer

[4] Ronggao Chen, et al. LY2228820 induces synergistic anti-cancer effects with anti-microtubule chemotherapeutic agents independent of P-glycoprotein in multidrug resistant cancer cells

[5] Robert M Campbell, et al. Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity

Related p38 MAPK Products
SSK1

SSK1 is a senescence-specific killing compound and is a precursor for β-galactosidase, which can reduce the inflammatory response. SSK1 can activate the phosphorylation of p38 MAPK and MKK3/MKK6 in senescent cells, promote mitochondrial DNA damage and selectively killed senescent cells.

p38 MAP Kinase Inhibitor III

p38 MAP Kinase Inhibitor III is a p38 MAPK inhibitor with an IC50 of 0.9 μM. p38 MAP Kinase Inhibitor III also inhibits IL-1β and TNF-α release with IC50 values of 0.37 μM and 0.044 μM, respectively.

(R)-STU104 

(R)-STU104 is a potent and orally active TAK1-MKK3 interaction inhibitor with IC50s of 0.58 μM and 4.0 μM for TNF-α and MKK3 phosphorylation.

SB 706504 

SB 706504 is a potent p38 MAPK inhibitor that inhibits Lipopolysaccharides-stimulated inflammatory gene expression in macrophages in chronic obstructive pulmonary disease (COPD).

RWJ-67657

RWJ-67657 (JNJ 3026582) is an orally active and selective p38α and p38β MAPK inhibitor with IC50s of 1 and 11 μM, respectively.

  Catalog
Abmole Inhibitor Catalog




Keywords: Ralimetinib dimesylate, LY2228820 dimesylate; LY2228820 2MsOH supplier, p38 MAPK, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.